About Anthony H. Wild, PhD
Tony is an investor in and on the boards of a number of privately-held healthcare companies in the US and Europe, helping to found BOWS Pharma of Switzerland as well as Sprout Pharmaceuticals and Slate Pharmaceuticals in the US.
Prior to this, he was a founder of MedPointe Pharmaceuticals Inc. formed in 2001 around the acquisition of the Carter-Wallace Company and became its Chairman and first CEO. MedPointe was successfully sold in August 2007 to MEDA AB of Sweden.
Earlier in his career he held a succession of international management positions in Schering-Plough Inc. in Switzerland, Sweden, South Africa, the Netherlands, the US and Japan, before moving to the Warner-Lambert Company as President of its Global Pharmaceutical Sector (1995 – 2000).
Current board positions include several U.S. privately-held healthcare companies. He also serves on the board of advisors to Auven Therapeutic Holdings LP, a diversified international biopharmaceutical investment fund, and is an advisor to HBM Bioventures, a Swiss healthcare investment firm.
Prior public-company board assignments include Bioglan Ltd (UK), Allergan Inc. (USA), Variagenics Inc. (USA), Millennium Pharmaceuticals Inc. (USA), Fovea Pharmaceuticals S.A. (France), and Ranbaxy Laboratories Ltd, (India).
Dr. Wild is an Honorary Fellow of Churchill College, University of Cambridge (UK) and is a member of its Board of Development. He is also an Honorary Morrell Fellow of the University of York (UK).
He is a past Chairman of the International Section of Pharmaceutical Research & Manufacturers of America (PhRMA) and a past Governor of the American Chamber of Commerce in Japan (ACCJ).
Dr. Wild graduated in 1968 from the University of York (UK) with a B.A. (Hons) degree in chemistry and holds a PhD in physical chemistry from the University of Cambridge (1971).
He resides in Lucerne, Switzerland with his wife Anna.